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Hormone secretion, a main feature of neuroendocrine tumours
(NET), has multiple consequences on the work-up aimed at estab-
lishing the diagnosis and the prognosis of these tumours.
Furthermore, NET may be associated as part of a hereditary
syndrome. A wide spectrum of so-called ‘eutopic or ectopic’
hormone secretions of varying sensitivity and specificity may be
considered according to the NET primary under examination. In
the cases of medullary thyroid carcinoma (MTC) and phaeochromo-
cytoma, serum calcitonin (CT) and 24-h urinary metanephrines are
respectively highly sensitive biological markers of these tumors
(Ghillani et al, 1989; Héron et al, 1996) but not specific for any
given NET primary (Baudin et al, 1999; Ciofu et al, 1999;
Leboulleux et al, 1999). Indeed, secretion of CT and even 24-h
urinary metanephrines has also been reported in endodermic-
derived gastro-enteropancreatic (GEP) NET (Baudin et al, 1999;
Ciofu et al, 1999). The biological characterization of NET with
other hormonal markers may help determine the anatomic site of
each primary. We report our experience with 2 biological NET
markers, namely chromogranin A (CgA) and the a-subunit of
glycoprotein hormones (GPa). 
CgA detection is a major step in the diagnosis of NET
(Wiedenmann and Huthner, 1989; Deftos, 1991; Öberg, 1996;
Nobels et al, 1997; Ferrari et al, 1998). Elevated serum CgA levels
have been demonstrated in various NET primaries with varying
sensitivity (Baudin et al, 1998; Ferrari et al, 1998). Few studies
have explored CgA sensitivity in MTC and phaeochromocytoma
which varies between 28–100% and 76–100% respectively. Only
one study has specified the relationship between CgA and CT
levels in MTC patients using an in-house method for CT measure-
ment (Blind et al, 1992) and 24-h urinary metanephrine excretion
in phaeochromocytoma patients, analysed by high-performance
liquid chromatography (HPLC), has seldom been considered a
reference measurement technique (Héron et al, 1996). In addition,
in phaeochromocytoma patients, data on the follow-up of CgA
measurements are scarce. 
Secretion of GPa has been reported in gastroenteropancreatic-
derived NET (GEP NET), including midgut-derived NET,
(Norheim et al, 1987; Öberg, 1996; Nobels et al, 1997) but also 
in patients with neuroectodermic-derived NET including 
patients with MTC and phaeochromocytoma (Nobels et al, 1997).
In contrast, in a previous study investigating 130 gastro-enteropan-
creatic NET of various origins, we found an elevated GPa level
exclusively in foregut-derived NET (Baudin et al, 1998).
Moreover, in a subsequent preliminary study, we were unable to
demonstrate GPa secretion in MTC patients (Leboulleux et al,
1999). We therefore put forward the hypothesis that GPa secretion
might be a specific biological marker of foregut-derived NET in
patients with neuroendocrine tumours. The sensitivity of GPa in
neuroectodermic-derived NET had to be assessed using highly
specific immunoradiometric assays (IRMA) to test this hypothesis. 
We therefore conducted the present study to investigate (i) the
sensitivity of GPa in patients with neuroectodermic-derived NET,
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(MTC and phaeochromocytoma); (ii) CgA sensitivity in these
tumours and its relationship with calcitonin and with 24-h urinary
metanephrine measurements in MTC patients and in phaeochro-
mocytoma patients respectively, using referenced assays and (iii)
the potential interest of CgA in the follow-up of phaeochromo-
cytoma patients. 
PATIENTS AND METHODS 
Patients 
61 patients with MTC, and 17 patients with phaeochromocytoma
(13 eutopic, 4 ectopic) were studied consecutively. There were 37
females and 41 males, with a mean age at diagnosis of 40 ± 12
years (mean ± SEM, range: 2–78 years). Among MTC patients, 20
patients had a familial form of the disease (either multiple
endocrine neoplasia (MEN) type 2A or MEN type 2B, or familial
MTC), and 41 had a sporadic MTC. All patients with MTC had
undergone a thyroidectomy, and 25 patients had been resubmitted
to surgery for neck or mediastinum recurrences. 8 patients had 
also been treated with external beam radiotherapy, and 8 with
chemotherapy (Schlumberger et al, 1995). At the time of the
present study, 16 patients had an undetectable plasma calcitonin
(CT) level. 45 patients had an elevated CT level and were consi-
dered as having persistent disease. These 45 patients underwent
the following examinations: neck and liver ultrasound (US),
computed tomography (CT scan) of the thorax and abdomen and a
bone scintigraphy. Distant metastases were discovered in 16
patients. 
Among phaeochromocytoma patients, 5 had a familial form 
of the disease (either MEN 2A, Von Hippel-Lindau disease, or
neurofibromatosis type 1), and 12 had a sporadic phaeochromo-
cytoma. Ectopic phaeochromocytoma was diagnosed in 4 patients,
defined as neuroendocrine tumours arising from the extra-adrenal
paraganglion system. When the differential diagnosis between
ectopic phaeochromocytoma and GEP NET was dubious, im-
munohistochemistry using epithelial markers that are positive in
GEP NET but negative in phaeochromocytoma was used. All
patients with phaeochromocytoma had undergone surgical removal
of the tumour, and 6 had had further surgery for local 
or distant recurrences. 5 patients were treated with 131I-
metaiodobenzyl guanidine (MIBG) and 5 with chemotherapy
(Averbuch et al, 1988). The following examinations were performed
in patients with persistent or recurrent disease: abdominal ultra-
sound, abdominal or thoracic CT scan or magnetic resonance
imaging (MRI), as well as MIBG scintigraphy. Somatostatin
receptor scintigraphy was performed in patients with an ectopic or a
malignant phaeochromocytoma. At the time of our study, 7 patients
were apparently free of disease (with normal catecholamines and
metabolites and no morphological evidence of tumour) and 10
patients had persistent or recurrent disease including 7 patients with
high urinary catecholamine and metabolite excretion, and 3 patients
with a locoregional (n = 1) or a metastatic recurrence (n = 2) of a
nonfunctioning ectopic phaeochromocytoma. 
In 5 phaeochromocytoma patients with elevated CgA, serial
measurements were compared to the results of morphological
investigations (follow-up: 14 ± 1 months). Results were also
compared to urinary metanephrine plus normetanephrine excretion
in 3 of these 5 patients. 
No patient had known concomitant MTC and phaeochromo-
cytoma at the time of the study, as demonstrated by a normal CT
level in phaeochromocytoma patients and normal 24-h urinary
metanephrine excretion in MTC patients. Patients with renal insuf-
ficiency (serum creatinine > 125 mmol–1 1) were excluded. 
Methods 
All samples were collected after overnight fasting and measured at
the same time. Serum CgA was measured using the CgA-Riact kit
(Cis Bio International, Gif-sur-Yvette, France, normal < 100 mg l–1),
a two-site immunoradiometric assay (IRMA) based on mono-
clonal antibodies that bind to 2 distinct epitopes within the central
domain of CgA (Degorce et al, 1999). Serum GPa (normal in men
and premenopausal women < 1 mg l–1; normal in post-menopausal
women < 3 mg l–1) was measured using a specific IRMA, as previ-
ously described (Ozturk et al, 1987). CT was measured using 
the ELSA-hCT kit (Cis Bio International; normal < 10 ng l–1).
CEA was measured using the Enzymum-test CEA kit (Boehringer,
Mannheim, Germany; normal < 7 mg l–1). 24-h urinary catech-
olamine and metabolite excretion was measured using HPLC with
a reverse phase column and amperometric detection, after specific
extraction, as previously described (Ciofu et al, 1999). Results
were indexed on 24-h urinary creatinine (metanephrine, normal 
< 400 nmol mmol–1 creatinine; normetanephrine, normal < 500
nmol mmol–1 creatinine) (Héron et al, 1996). Normal values, as
defined by previous studies, were used to classify the results of
these markers, as well as the 160 mg l–1 cut-off value for CgA
which is associated with a 95% specificity rate (Baudin et al,
1998). The study was performed after obtaining the informed
consent of each patient. 
RESULTS 
Results are summarized in Figures 1–3. 
Serum CgA levels in MTC patients (Figure 1) 
Among 61 MTC patients, the serum CgA level was normal in 45
patients. It was increased in 16 patients (26%), including 12 (27%)
of the 45 MTC patients with abnormal CT levels and 4 (25%) of
the 16 disease-free patients with normal CT levels. Only, 2 of these
4 patients had a significantly increased CgA level (>160 mg l–1).
None of these 4 patients had a history of hypertension or
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Figure 1 Serum CgA concentrations in 61 patients with medullary 
thyroid carcinoma. Individual levels are represented by dots. The dash 
lines represent the upper limit of the normal range (CT < 10 ng l–1, 
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epigastralgy and all had a normal ionized calcaemia and PTH 1-84
levels. 12 patients had both increased CgA and CT levels: all but 1
patient had a CT level above 1000 ng l–1 (CgA mean, 304 mg l–1;
median 185 mg l–1; range, 126–1065 mg l–1). 
Serum CgA levels in patients with phaeochromocytoma
(Figure 2) 
The CgA level was normal in all the 7 disease-free patients. Of the
7 patients with elevated urinary catecholamine and metabolite
excretion, 5 (71%) had an increased CgA level, in all cases above
160 mg l–1 (CgA mean 512 mg l–1; median 370 mg l–1; range,
187–1125 mg l–1). In the 3 patients with an ectopic phaeochromo-
cytoma and normal urinary catecholamine and metabolite excre-
tion but with morphological evidence of recurrent disease, 2 (67%)
had an elevated CgA level (> 160 mg l–1), respectively at 386 and
1289 mg l–1. 
CgA in the follow-up of phaeochromocytomas 
(Figure 3) 
In the 5 phaeochromocytoma patients exhibiting elevated CgA,
follow-up CgA measurements were compared to the results of
morphological investigations which demonstrated one objective
response in a patient who had received MIBG radionucleide
therapy and progressive disease in the 4 other patients. In all cases,
follow-up CgA measurements were correlated with the tumour
burden. In 3 of these 5 patients, the course of follow-up CgA
values was compared to the 24-h urinary metanephrine levels. A
close relationship between both secretions was found in all
patients, as illustrated in Figure 3. 
GPa levels in patients with MTC or
phaeochromocytoma 
Among the 44 patients with either MTC and increased CT (n = 35)
or recurrent phaeochromocytoma (n = 9), GPa was slightly
elevated in only 2 women: one with a history of  mg l–1) and one, a
38-year-old, who had a slightly increased GPa level (0.55 mg l–1). 
DISCUSSION 
In our study, serum CgA was elevated in 27% of MTC patients
with hypercalcitoninaemia, and in only 56% of metastatic MTC
with markedly elevated CT (> 10 000 ng l–1). Given its low sens-
itivity in MTC patients, CgA does not appear to be capable of
competing with CT for the diagnosis of MTC. This CgA sens-
itivity was in the lower range of values described in previous
studies (O’Connor and Deftos, 1986; Blind et al, 1992; Nobels et
al, 1997). Such discrepancies may partly be explained by different
biological assays used to measure CgA. We used a 2-site ‘sand-
wich’ IRMA based on monoclonal antibody recognition of the
central unprocessed domain of CgA. The results obtained with this
assay may be interpreted differently from those obtained with an
radioimmunologic assay based on polyclonal antibody recognition
of the entire CgA molecule as well as derived peptides (Degorce 
et al, 1999). It is noteworthy that 2 of the 23 MTC or phaeochro-
mocytoma patients, considered free of disease, had an elevated
CgA level exceeding the 160 mg l–1 cut-off value. The specificity
of CgA in this study is therefore in the same range as that previ-
ously reported using the same immunoassay (Baudin et al, 1998).
None of the classic false positive CgA results were found in these
patients (O’Connor et al, 1989; Takiyyudin et al, 1990; Cryer et al,
1991; Deftos, 1991; Takiyyudin et al, 1991; Nobels et al, 1997;
Sanduleanu et al, 1999). Above all associated NET as part of
multiple endocrine neoplasia were excluded. As suggested by one
previous study, a significant increase was found in CgA exclu-
sively in MTC patients with advanced stage disease (Blind et al,
1992). Our study specifies the relationship between CgA and CT
secretion using a sensitive commercial kit which may help physi-
cians interpret CgA levels in these patients. All but 1 patient with a
CT level below 1000 ng l–1 were found to have a normal CgA
value and only 2 MTC patients were found to have a CgA level
above 400 mg l–1. We strongly recommend therefore, that MTC
patients with a significantly elevated CgA level should undergo
systematic screening for an associated phaeochromocytoma as part
of a multiple endocrine syndrome, type 2. Indeed, serum CgA was
elevated in 70% (7/10) of patients with either a functioning or a
metastatic non-functioning phaeochromocytoma. These results
confirm the impact of the NET origin on CgA sensitivity. The
adrenal medulla is a well-known major tissue source of CgA
(Takiyyuddin et al, 1990). Previous studies reported a 76–100%
sensitivity of CgA in phaeochromocytoma patients with cate-
cholamine secretion (O’Connor and Deftos, 1986; Boosma et al,
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Figure 2 Serum CgA concentrations in 17 patients with
phaeochromocytoma. Individual levels are represented by dots. The dash
lines represent the upper limit of the normal range (urinary MN + NMN:
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Figure 3 Evolution of CgA and 24 h urinary metanephrine plus
normetanephrine excretion in a 54-year-old man with progressive lung and
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1995; Kimura et al, 1997; Nobels et al, 1997; Stidsberg and
Husebye, 1997; Yanaihara et al, 1999). Apart from the various
methodological techniques used to measure CgA, the characteris-
tics of our phaeochromocytoma patient population, namely the
high number of malignant and ectopic tumours, may explain the
lower CgA sensitivity, found in this study. Like Hsiao et al (1991),
we confirm a lower sensitivity of CgA compared to urinary
metanephrine and normetanephrine, considered the most sensitive
markers of phaeochromocytoma, measured with HPLC, the most
reliable method of measurement (Héron et al, 1996). Previous
studies have investigated the interest of CgA in phaeochromo-
cytoma patients during the early postoperative period (Boosma et
al, 1995; Stridsberg and Husebye, 1997) and one has recom-
mended its use in this context (Stridsberg and Husebye, 1997). To
our knowledge, no data have yet been published on the interest of
serial CgA measurements in the follow-up of patients with malig-
nant phaeochromocytoma. In all the 5 such patients studied, a
close relationship was found between CgA levels and either the
tumour burden or the course of 24-h urinary metanephrine. As
serum CgA measurement can be readily obtained to monitor func-
tioning phaeochromocytomas compared to urinary tests, we
recommend that CgA be used as a follow-up marker for routine
measurements in phaeochromocytoma. Of note, recent studies
suggest that serum metanephrine and normetanephrine levels may
have a high sensitivity in phaeochromocytoma patients (Boosma
et al, 1995; Eisenhofer et al, 1999). The mechanisms of CgA
secretion in patients with non-functioning phaeochromocytomas
remain unclear. In these patients, CgA should also be screened by
routine measurement. 
No significant secretion of GPa was found in patients with
either MTC or phaeochromocytoma in this study. Only 2 patients
had slightly increased levels of GPa in the range of those found
in postmenopausal women. These results contrast with one
previous study, which found elevated GPa levels in 5 of 26
MTC, 1 of 9 phaeochromocytomas and 3 of 25 paragangliomas
(Nobels et al, 1997). This discrepancy may be due to different
specificities in the methods of measurement. A 2-site IRMA,
using at least one monoclonal antibody directed to a specific-free
GPa antigenic site was used in this study to improve the speci-
ficity of GPa measurement (Ozturk et al, 1987; Marcillac et al,
1992). Our results suggest that in NET patients with elevated CT
secretion, serum GPa may be a useful marker in doubtful cases
to differentiate MTC patients from foregut-derived GEP-NET
patients in whom GPa is frequently elevated (Leboulleux et al,
1999). 
In conclusion, we do not recommend serum CgA measurement
for the diagnosis of MTC patients. CgA measurement may be
useful during the follow-up of patients with phaeochromocytoma
and should be screened in patients with a non-functioning
phaeochromocytoma. No GPa secretion was found in MTC and
phaeochromocytoma patients. In NET patients with elevated CT
secretion, serum GPa measurement may help differentiate MTC
or phaeochromocytoma from other GEP-NET patients. 
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